Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products

2020 ◽  
Author(s):  
Joaquim Vives ◽  
Luciano Rodríguez ◽  
Maria Isabel Coca ◽  
Laura Reales ◽  
Raquel Cabrera-Pérez ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Multipotent Mesenchymal Stromal Cells ◽  
Clinical Grade

The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering

Biomaterials ◽  
2009 ◽  
Vol 30 (20) ◽  
pp. 3415-3427 ◽  
Author(s):  
Robert Pytlík ◽  
David Stehlík ◽  
Tomáš Soukup ◽  
Marie Kalbáčová ◽  
František Rypáček ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Multipotent Mesenchymal Stromal Cells ◽  
Clinical Grade

scholarly journals Clinical Application of Human Mesenchymal Stromal Cells for Bone Tissue Engineering

2010 ◽  
Vol 2010 ◽  
pp. 1-12 ◽  
Author(s):  
Anindita Chatterjea ◽  
Gert Meijer ◽  
Clemens van Blitterswijk ◽  
Jan de Boer
Keyword(s):  
Tissue Engineering ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Clinical Studies ◽  
Bone Graft Substitute ◽  
Conclusive Evidence ◽  
Bone Tissue Regeneration ◽  
Bone Apposition

The gold standard in the repair of bony defects is autologous bone grafting, even though it has drawbacks in terms of availability and morbidity at the harvesting site. Bone-tissue engineering, in which osteogenic cells and scaffolds are combined, is considered as a potential bone graft substitute strategy. Proof-of-principle for bone tissue engineering using mesenchymal stromal cells (MSCs) has been demonstrated in various animal models. In addition, 7 human clinical studies have so far been conducted. Because the experimental design and evaluation parameters of the studies are rather heterogeneous, it is difficult to draw conclusive evidence on the performance of one approach over the other. However, it seems that bone apposition by the grafted MSCs in these studies is observed but not sufficient to bridge large bone defects. In this paper, we discuss the published human clinical studies performed so far for bone-tissue regeneration, using culture-expanded, nongenetically modified MSCs from various sources and extract from it points of consideration for future clinical studies.

Sign in / Sign up

Export Citation Format

Share Document